Mira Dx Licenses miRNA Technology for Breast Cancer from Yale | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mira Dx today announced it is licensing technology from Yale University for the identification of patients at risk for triple negative breast cancer.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.